Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes

Figure 2

FCM-based assessment of the cytotoxicity of NK effector (E) cells against target (T) cells at different E : T ratios: (a) NK-92MI/CD16a (CD16-dependent) or (b) NK-92MI (CD16-independent) cells were incubated for 4 hr with the CFSE (2.5 µM)-prelabeled K562, U266, RPMI 8226, and MM.1S cells. The percentage of dead target cells (CFSE⁺FVD⁺) was analyzed among the total FVD dye-labeled cells (n = 5), and (c) freshly eNKs were collected and washed, and then were cocultured with CFSE-labeled K562. The percentage of eNK (day 21) was 75.4% ± 11.3% (D-eNK, left panel, n = 3) and 69.9% (Pt-eNK, right panel, n = 1). Results are presented as mean ± SD of independent experiments, respectively. The percentage of labeled control cells was subtracted in all assays.

(a)

(b)

(c)